FCM
ATRA icon

Farallon Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Farallon Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-60,000
Closed -$12.8M – 120
2020
Q1 		$12.8M Buy
60,000
+46,612
+348% +$14.8M 0.11% 75
2019
Q4 		$5.51M Buy
+13,388
New +$4.62M 0.04% 110

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Farallon Capital Management's ATRA Position: Q2 2020 in Review

Farallon Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2020, closing a stake of 60,000 shares — an estimated $12.8M sold.

Farallon Capital Management first reported a position in ATRA in Q4 2019 and held it in 2 quarters. The position peaked at $12.8M in Q1 2020. 122 funds tracked by Wall St. Rank hold ATRA as of Q2 2020.

  • Farallon Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Farallon Capital Management sold 60,000 Atara Biotherapeutics shares in Q2 2020, an estimated $12.8M.
  • Farallon Capital Management first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 2 quarters.
  • Farallon Capital Management's Atara Biotherapeutics position peaked at $12.8M in Q1 2020.
  • 122 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2020.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.